Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenue
70,492
46,716
44,286
41,618
45,389
39,175
Revenue Growth (YoY)
69%
5%
6%
-8%
16%
5%
Cost of Revenue
19,350
13,049
13,205
12,628
13,695
12,255
Gross Profit
51,142
33,667
31,081
28,990
31,694
26,920
Selling, General & Admin
14,056
9,543
9,096
8,833
10,410
9,457
Research & Development
11,484
7,842
7,393
6,504
6,705
5,689
Operating Expenses
34,730
23,585
22,379
20,465
21,646
18,555
Other Non Operating Income (Expenses)
49
--
-332
-644
-67
-39
Pretax Income
11,843
6,175
6,698
6,251
10,422
7,798
Income Tax Expense
2,204
1,043
1,204
1,017
2,006
1,558
Net Income
12,487
7,813
5,560
5,400
8,371
6,223
Net Income Growth
125%
41%
3%
-35%
35%
-49%
Shares Outstanding (Diluted)
1,219.84
1,220.4
1,256.1
1,256.4
1,256.9
1,257.9
Shares Change (YoY)
-3%
-3%
0%
0%
0%
0%
EPS (Diluted)
10.23
6.4
4.42
4.29
6.66
4.95
EPS Growth
133%
45%
3%
-36%
35%
-49%
Free Cash Flow
5,959
10,917
5,886
7,352
8,325
8,479
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
72.55%
72.06%
70.18%
69.65%
69.82%
68.71%
Operating Margin
23.28%
21.58%
19.64%
20.48%
22.13%
21.35%
Profit Margin
17.71%
16.72%
12.55%
12.97%
18.44%
15.88%
Free Cash Flow Margin
8.45%
23.36%
13.29%
17.66%
18.34%
21.64%
EBITDA
19,048
11,858
10,540
10,541
12,188
10,046
EBITDA Margin
27.02%
25.38%
23.79%
25.32%
26.85%
25.64%
D&A For EBITDA
2,636
1,776
1,838
2,016
2,140
1,681
EBIT
16,412
10,082
8,702
8,525
10,048
8,365
EBIT Margin
23.28%
21.58%
19.64%
20.48%
22.13%
21.35%
Effective Tax Rate
18.61%
16.89%
17.97%
16.26%
19.24%
19.97%
Follow-Up Questions
What are Sanofi's key financial statements?
According to the latest financial statement (Form-10K), Sanofi has a total asset of $126,806, Net profit of $7,813
What are the key financial ratios for SNY?
Sanofi's Current ratio is 2.28, has a Net margin is 16.72, sales per share of $38.27.
How is Sanofi's revenue broken down by segment or geography?
Sanofi largest revenue segment is Total Vaccine, at a revenue of 7,936,000,000 in the most earnings release.For geography, United States is the primary market for Sanofi, at a revenue of 22,176,000,000.
Is Sanofi profitable?
yes, according to the latest financial statements, Sanofi has a net profit of $7,813